Neuphoria Therapeutics (NEUP) Price & Analysis

Q: What was Neuphoria Therapeutics’s price range in the past 12 months?

Neuphoria Therapeutics lowest stock price was $2.77 and its highest was $21.40 in the past 12 months.

Q: What is Neuphoria Therapeutics’s market cap?

Neuphoria Therapeutics’s market cap is $21.03M.

Q: When is Neuphoria Therapeutics’s upcoming earnings report date?

Neuphoria Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is 307 days ago.

Q: Is Neuphoria Therapeutics overvalued?

According to Wall Street analysts Neuphoria Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Neuphoria Therapeutics pay dividends?

Neuphoria Therapeutics does not currently pay dividends.

Q: What is Neuphoria Therapeutics’s EPS estimate?

Neuphoria Therapeutics’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Neuphoria Therapeutics have?

Neuphoria Therapeutics has 5,377,329 shares outstanding.

Q: Which hedge fund is a major shareholder of Neuphoria Therapeutics?

Currently, no hedge funds are holding shares in NEUP

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

303 Followers

NEUP Stock Chart & Stats

$3.91

-$0.37(-10.36%)

At close: Jan 08 4:00 PM EST

$3.91

-$0.37(-10.36%)

Day’s Range― - ―

52-Week Range$2.77 - $21.40

Previous CloseN/A

Volume31.57K

Average Volume (3M)89.21K

Market Cap

$21.03M

Enterprise ValueN/A

Total Cash (Recent Filing)$13.65M

Total Debt (Recent Filing)$85.21K

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Feb 20, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding5,377,329

10 Day Avg. Volume91,705

30 Day Avg. Volume89,214

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)<0.01

Price to Sales (P/S)0.48

P/FCF Ratio0.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$9.77

Price Target Upside149.87% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StabilityWith a cash balance of $14.2M and access to $22M on its ATM facility, there should be sufficient funding into 2027.

Market ValuationThe market cap is now under cash value, presenting an opportunity as the analyst maintains a Buy recommendation based on the PTSD opportunity.

Strategic PartnershipsNeuphoria continues to benefit from its ongoing collaboration with Merck, which includes MK-1167 in an Alzheimer's disease Phase 2 study.

Bears Say

Clinical Trial SetbacksThe Phase 3 AFFIRM-1 trial evaluating BNC210 for the treatment of social anxiety disorder did not meet its primary or secondary endpoints, representing a major setback.

Share Price ImpactThe P3 AFFIRM-1 study of BNC210 in social anxiety disorder (SAD) missed its primary endpoint, leading to a significant drop in NEUP shares.

Strategic UncertaintyOngoing issues with Lynx1 Master Fund create added uncertainty, as there is a disagreement on valuation and strategic direction.

Neuphoria Therapeutics News

Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees

Neuphoria Therapeutics (NEUP) announced that Institutional Shareholders Services, ISS, a leading independent proxy advisory firm, has issued a...

16d ago

NEUP

Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Neuphoria Therapeutics (NEUP) to $7 from $21 and keeps a...

19d ago

NEUP

Neuphoria Therapeutics responds to Lynx1’s revised indication of interest

Neuphoria Therapeutics (NEUP) issued the following statement in response to dissident stockholder, Lynx1 Master Fund’s, revised indication of...

20d ago

NEUP

Neuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1

The company states: “Neuphoria Therapeutics (NEUP) issued the following statements to address what Neuphoria strongly believes is a...

23d ago

NEUP

Neuphoria Therapeutics Shareholders Align on Key Proposals

Neuphoria Therapeutics ( ($NEUP) ) has shared an update. On December 12, 2025, Neuphoria Therapeutics held its Annual...

7d ago

NEUP

Neuphoria Therapeutics urges stockholders to vote for company nominees

Neuphoria Therapeutics (NEUP) issued a letter to its stockholders regarding Neuphoria’s 2025 Annual Meeting of Stockholders, which is...

1M ago

NEUP

Neuphoria initiates strategic review, confirms receipt of indication of interest

Neuphoria Therapeutic announced, as previously disclosed, the initiation of a review of strategic alternatives to advance the Company’s...

1M ago

NEUP

Neuphoria Therapeutics Declares Dividend Rights Plan

Neuphoria Therapeutics ( ($NEUP) ) has shared an announcement. On October 25, 2025, Neuphoria Therapeutics‘ Board of Directors...

2M ago

NEUP

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

2M ago

FUSE

NEUP

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

2M ago

IBIO

NEUP

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

2M ago

IBIO

NEUP

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

TipRanks offers insight into the biggest stock market stories worth reading on Tuesday. ...

2M ago

Why Is Neuphoria Therapeutics Stock (NEUP) Down 65% Today?

Neuphoria Therapeutics stock fell hard on Tuesday after the company posted results from a Phase 3 clinical trial. ...

2M ago

NEUP

Morning Movers: General Motors and RTX higher following Q3 reports

Stock futures hovered near record highs, though upside momentum has been muted in early trading as investors weigh...

2M ago

NEUP FAQ

What was Neuphoria Therapeutics’s price range in the past 12 months?

Neuphoria Therapeutics lowest stock price was $2.77 and its highest was $21.40 in the past 12 months.

What is Neuphoria Therapeutics’s market cap?

Neuphoria Therapeutics’s market cap is $21.03M.

When is Neuphoria Therapeutics’s upcoming earnings report date?

Neuphoria Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is 307 days ago.

How were Neuphoria Therapeutics’s earnings last quarter?

Currently, no data Available

Is Neuphoria Therapeutics overvalued?

According to Wall Street analysts Neuphoria Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neuphoria Therapeutics pay dividends?

Neuphoria Therapeutics does not currently pay dividends.

What is Neuphoria Therapeutics’s EPS estimate?

Neuphoria Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neuphoria Therapeutics have?

Neuphoria Therapeutics has 5,377,329 shares outstanding.

What happened to Neuphoria Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Neuphoria Therapeutics?

Currently, no hedge funds are holding shares in NEUP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics (NEUP) Earnings & Revenues

Historic Earnings Reports

NEUP Stock 12 Month Forecast

Average Price Target

$9.77

▲(149.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","48":"$48","12.75":"$12.75","24.5":"$24.5","36.25":"$36.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,12.75,24.5,36.25,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"Jun<br/>2024","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.39,5.59076923076923,6.791538461538462,7.992307692307692,9.193076923076923,10.393846153846154,11.594615384615384,12.795384615384616,13.996153846153845,15.196923076923078,16.397692307692306,17.59846153846154,18.79923076923077,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.39,4.803846153846154,5.217692307692308,5.631538461538462,6.045384615384615,6.4592307692307696,6.873076923076923,7.286923076923077,7.700769230769231,8.114615384615384,8.528461538461539,8.942307692307693,9.356153846153845,{"y":9.77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.39,4.229230769230769,4.068461538461539,3.9076923076923076,3.7469230769230766,3.586153846153846,3.4253846153846155,3.2646153846153845,3.1038461538461535,2.943076923076923,2.7823076923076924,2.6215384615384614,2.460769230769231,{"y":2.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.28,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.64,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.28,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.8,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.28,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.08,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >